Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

OmniAb, Inc. (OABI) Financial Statements

OmniAb, Inc. (OABI) reported trailing twelve-month revenue of $38.5M (up 67.0% year on year) and net income of -$44.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$18.1M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

OABIOmniAb, Inc.Follow OABI — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
677.5M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
30 Oct, in 6 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue59.134.226.418.738.5
Gross profit———18.4—
Research & development48.456.555.147.843.5
Operating income-26.6-69.4-74.5-69.0-48.4
Pre-tax income-26.1-64.4-71.4-66.3-45.7
Income tax-3.7-13.7-9.4-1.5-1.4
Net income-22.3-50.6-62.0-64.8-44.3
Diluted EPS ($)-0.26-0.51-0.61-0.57-0.36
Diluted shares (mn)85.399.7102.4113.6—

USD millions · SEC XBRL

OmniAb, Inc. — questions

What is OmniAb, Inc.'s revenue?
$38.5M over the twelve months to 2026-06-30, up 67.0% year on year, from its 10-Q and 10-K filings.
What is OmniAb, Inc.'s net income?
-$44.3M over the twelve months to 2026-06-30.
What is OmniAb, Inc.'s free cash flow?
-$18.1M over the twelve months to 2026-06-30.
What are OmniAb, Inc.'s diluted earnings per share?
$-0.36 over the twelve months to 2026-06-30.

Every figure on this page comes from OmniAb, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.